1)Caprioli J, Garway-Heath DF:International Glaucoma Think Tank. A critical reevaluation of current glaucoma management:International Glaucoma Think Tank, July 27-29, 2006, Taormina, Sicily. Ophthalmology 114:S1-S41, 2007
2)Weinreb RN, Friedman DS, Fechtner RD et al:Risk assessment in the management of patients with ocular hypertension. Am J Ophthalmol 138:458-467, 2004
3)Quigley HA, Addicks EM, Green WR:Optic nerve damage in human glaucoma. Ⅲ. Quantitative correlation of nerve fiber loss and visual field defect in glaucoma, ischemic neuropathy, papilledema, and toxic neuropathy. Arch Ophthalmol 100:135-146, 1982
4)Quigley HA, Addicks EM:Quantitative studies of retinal nerve fiber layer defects. Arch Ophthalmol 100:807-814, 1982
5)Quigley HA, Dunkelberger GR, Green WR:Retinal ganglion cell atrophy correlated with automated perimetry in human eyes with glaucoma. Am J Ophthalmol 107:453-464, 1989
6)Kerrigan-Baumrind LA, Quigley HA, Pease ME et al:Number of ganglion cells in glaucoma eyes compared with threshold visual field tests in the same persons. Invest Ophthalmol Vis Sci 41:741-748, 2000
7)Harwerth RS, Carter-Dawson L, Smith EL 3rd et al:Scaling the structure―function relationship for clinical perimetry. Acta Scand Ophthalmol 83:448-455, 2005
8)Naka M, Kanamori A, Tatsumi Y et al:Comparison of mean deviation with AGIS and CIGTS scores in association with structural parameters in glaucomatous eyes. J Glaucoma(in press)
9)Garway-Heath DF, Caprioli JM, Fitzke FW et al:Scaling the hill of vision:the physiological relationship between light sensitivity and ganglion cell numbers. Invest Ophthalmol Vis Sci 41:1774-1782, 2000